IM Cannabis Corp. (IMCC)
USD 1.37
(0.74%)
USD 1.37
(0.74%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 48.8 Million CAD | -10.18% |
| 2022 | 54.33 Million CAD | 0.06% |
| 2021 | 54.3 Million USD | 241.72% |
| 2020 | 15.89 Million CAD | 75.12% |
| 2019 | 9.07 Million CAD | 74.6% |
| 2018 | 5.19 Million CAD | 18.3% |
| 2017 | 4.39 Million CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| 2004 | - CAD | 0.0% |
| 2003 | - CAD | -100.0% |
| 2002 | 34.58 Thousand CAD | 0.0% |
| 2001 | 34.58 Thousand CAD | -68.81% |
| 2000 | 110.89 Thousand CAD | 10.89% |
| 1999 | 100 Thousand CAD | 0.0% |
| 1998 | 100 Thousand CAD | -83.33% |
| 1997 | 600 Thousand CAD | -45.45% |
| 1996 | 1.1 Million CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 14.75 Million CAD | 22.27% |
| 2024 Q1 | 12.06 Million CAD | 12.76% |
| 2023 Q3 | 38.1 Million CAD | 188.53% |
| 2023 Q2 | 13.2 Million CAD | 0.26% |
| 2023 FY | 48.8 Million CAD | -10.18% |
| 2023 Q4 | 10.69 Million CAD | -71.93% |
| 2023 Q1 | 13.17 Million CAD | -8.91% |
| 2022 Q2 | 23.82 Million CAD | 1.07% |
| 2022 Q1 | 23.56 Million CAD | 17.68% |
| 2022 FY | 54.33 Million CAD | 0.06% |
| 2022 Q4 | 14.46 Million CAD | 2.05% |
| 2022 Q3 | 14.17 Million CAD | -40.51% |
| 2021 Q1 | 8.76 Million CAD | 78.92% |
| 2021 Q4 | 20.02 Million USD | 39.15% |
| 2021 Q2 | 11.11 Million CAD | 26.75% |
| 2021 FY | 54.3 Million USD | 241.72% |
| 2021 Q3 | 14.39 Million CAD | 29.53% |
| 2020 Q1 | 1.34 Million CAD | -45.95% |
| 2020 FY | 15.89 Million CAD | 75.12% |
| 2020 Q2 | 3.75 Million CAD | 180.37% |
| 2020 Q4 | 4.9 Million CAD | -16.85% |
| 2020 Q3 | 5.89 Million CAD | 56.85% |
| 2019 Q1 | 1.95 Million CAD | 35.86% |
| 2019 Q4 | 2.47 Million CAD | 6.58% |
| 2019 Q3 | 2.32 Million CAD | 0.52% |
| 2019 FY | 9.07 Million CAD | 74.6% |
| 2019 Q2 | 2.31 Million CAD | 18.36% |
| 2018 Q2 | 1.27 Million CAD | 15.57% |
| 2018 Q4 | 1.43 Million CAD | 4.5% |
| 2018 Q1 | 1.1 Million CAD | 0.0% |
| 2018 FY | 5.19 Million CAD | 18.3% |
| 2018 Q3 | 1.37 Million CAD | 7.83% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | 4.39 Million CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2005 Q2 | - CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 FY | - CAD | 0.0% |
| 2004 Q2 | - CAD | 0.0% |
| 2004 Q3 | - CAD | 0.0% |
| 2004 Q4 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q1 | - CAD | 0.0% |
| 2003 FY | - CAD | -100.0% |
| 2003 Q4 | - CAD | 0.0% |
| 2002 FY | 34.58 Thousand CAD | 0.0% |
| 2002 Q3 | - CAD | 0.0% |
| 2002 Q1 | - CAD | -100.0% |
| 2002 Q4 | - CAD | 0.0% |
| 2002 Q2 | - CAD | 0.0% |
| 2001 Q4 | 9457.00 CAD | 29.55% |
| 2001 Q2 | 17.82 Thousand CAD | 172.53% |
| 2001 FY | 34.58 Thousand CAD | -68.81% |
| 2001 Q1 | 6541.00 CAD | -62.23% |
| 2001 Q3 | 7300.00 CAD | -59.05% |
| 2000 Q1 | - CAD | -100.0% |
| 2000 Q4 | 17.31 Thousand CAD | 1731800.0% |
| 2000 Q3 | 1.00 CAD | -100.0% |
| 2000 Q2 | 100 Thousand CAD | 0.0% |
| 2000 FY | 110.89 Thousand CAD | 10.89% |
| 1999 Q3 | 100 Thousand CAD | 0.0% |
| 1999 FY | 100 Thousand CAD | 0.0% |
| 1999 Q4 | 100 Thousand CAD | 0.0% |
| 1999 Q2 | 100 Thousand CAD | 200.0% |
| 1999 Q1 | -100 Thousand CAD | -200.0% |
| 1998 Q3 | 100 Thousand CAD | 0.0% |
| 1998 FY | 100 Thousand CAD | -83.33% |
| 1998 Q4 | 100 Thousand CAD | 0.0% |
| 1998 Q1 | -100 Thousand CAD | -133.33% |
| 1998 Q2 | 100 Thousand CAD | 200.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 FY | 600 Thousand CAD | -45.45% |
| 1997 Q4 | 300 Thousand CAD | 50.0% |
| 1996 FY | 1.1 Million CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 91.389% |
| Embecta Corp. | 1.12 Billion USD | 95.646% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 89.975% |
| Dynavax Technologies Corporation | 232.28 Million USD | 78.99% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 58.048% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 92.77% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 3.517% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -102.567% |
| SCYNEXIS, Inc. | 140.14 Million USD | 65.175% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -2430.675% |
| Cosmos Health Inc. | 53.37 Million USD | 8.567% |
| Journey Medical Corporation | 79.18 Million USD | 38.364% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -102.567% |
| Safety Shot Inc | 202.67 Thousand USD | -23980.525% |
| Alpha Teknova, Inc. | 36.68 Million USD | -33.039% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 89.49% |
| Bright Green Corporation | 401.49 Thousand USD | -12055.69% |
| Procaps Group, S.A. | 409.92 Million USD | 88.094% |
| Theratechnologies Inc. | 81.76 Million USD | 40.311% |
| Harrow Health, Inc. | 130.19 Million USD | 62.514% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -283.227% |
| Biofrontera Inc. | 34.07 Million USD | -43.242% |
| DURECT Corporation | 8.54 Million USD | -470.941% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 91.967% |
| Cronos Group Inc. | 88.84 Million USD | 45.066% |
| OptiNose, Inc. | 70.98 Million USD | 31.249% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 88.977% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -649.312% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 88.733% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -298.447% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -23.39% |
| Radius Health, Inc. | 2.88 Billion USD | 98.307% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -51.055% |
| ProPhase Labs, Inc. | 44.38 Million USD | -9.959% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 95.204% |
| Procaps Group S.A. | 409.92 Million USD | 88.094% |
| Alvotech | 91.43 Million USD | 46.624% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3648.387% |
| Viatris Inc. | 15.42 Billion USD | 99.684% |
| Rockwell Medical, Inc. | 83.61 Million USD | 41.63% |
| Aytu BioPharma, Inc. | 81 Million USD | 39.75% |
| SIGA Technologies, Inc. | 139.91 Million USD | 65.119% |
| Tilray Brands, Inc. | 788.94 Million USD | 93.814% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 61.949% |
| Shineco, Inc. | 9.8 Million USD | -397.906% |
| PetIQ, Inc. | 1.1 Billion USD | 95.571% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -406600.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.414% |
| Alimera Sciences, Inc. | 80.75 Million USD | 39.565% |
| Silver Spike Investment Corp. | 11.72 Million USD | -316.341% |
| Assertio Holdings, Inc. | 152.06 Million USD | 67.907% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -738.213% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -180.209% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4433.981% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -74.531% |
| Hempacco Co., Inc. | 4.04 Million USD | -1106.337% |
| Talphera, Inc. | 651 Thousand USD | -7396.774% |
| Alvotech | 91.43 Million USD | 46.624% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 84.585% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 96.236% |
| Currenc Group, Inc. | 53.25 Million USD | 8.359% |
| Kamada Ltd. | 144.75 Million USD | 66.286% |
| Indivior PLC | 1.09 Billion USD | 95.535% |
| Evoke Pharma, Inc. | 5.18 Million USD | -842.048% |
| Flora Growth Corp. | 76.07 Million USD | 35.844% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4433.981% |
| Evolus, Inc. | 202.08 Million USD | 75.85% |
| HUTCHMED (China) Limited | 837.99 Million USD | 94.176% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 92.426% |
| Akanda Corp. | 2.16 Million USD | -2159.39% |